tbuckley/cabot-search huggingface dataset:
Evidence for Antigen-Driven Development of Molecularly Classified Burkitt Lymphomas.
Authors: Heiko Trautmann, Anastasia Hadzidimitriou, Nikos Darzentas, Wolfram Klapper, Reiner Siebert, Hilmar Berger, Monika Szczepanowski, Michael Kneba, Claudia Philipp, Ralf Küppers, Kostas Stamatopoulos, Christiane Pott
Journal: Blood (2009)
Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.
Authors: Meletios A. Dimopoulos, Maria Roussou, Efstathios Kastritis, Maria Gavriatopoulou, Flora Zagouri, Magdalini Migkou, Charis Matsouka, Despina Barmparousi, Dimitrios Christoulas, Erasmia Psimenou, Irini Grapsa, Evangelos Terpos
Journal: Blood (2008)
Macrofocal Multiple Myeloma in Young Patients: A Distinct Entity with Favorable Prognosis.
Authors: Meletios A. Dimopoulos, Anastasia Pouli, Athanasios Angnostopoulos, Panagiotis Repoussis, Argyris Symeonidis, Souzana Delimbasi, Fotis Tsolakis, Constantinos Zervas
Journal: Blood (2005)
Rapid Detection of Pathogens Causing Sepsis in Neutropenic Hematologic Patients by a Multiplex PCR-Based Assay
Authors: Raffaella Greco, Daniela Clerici, Nicasio Mancini, Francesca Lorentino, Francesca Matteazzi, Alessandra Forcina, Maria Teresa Lupo Stanghellini, Luca Vago, Lara Crucitti, Elena Guggiari, Sarah Marktel, Andrea Assanelli, Matteo Carrabba, Bernardi Massimo, Jacopo Peccatori, Claudio Bordignon, Massimo Clementi, Fabio Ciceri, Consuelo Corti
Journal: Blood (2011)
Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response.
Authors: E. H. Lips, L. Mulder, S. A. Joosse, S. Savola, M. A. Vollebergh, L. F. Wessels, J. Wesseling, P. M. Nederlof, S. Rodenhuis
Journal: Journal of Clinical Oncology (2011)

10513 Background: Our group has previously employed array Comparative Genomic Hybridization (aCGH) to assess the genomic patterns of BRCA1-mutated breast cancers. We have shown that the so-called BRCA1-likeaCGH profile is also present in about half of all triple negative sporadic breast cancers and is predictive for benefit from bifunctional alkylating agents. As aCGH is a rather complex method, we translated the BRCA1aCGH profile to a Multiplex Ligation-dependent Probe Amplification (MLPA) assay, to identify both BRCA1-mutated breast cancers and sporadic cases with a BRCA1-likeaCGH profile. Methods: The most important genomic regions of the original aCGH based classifier (3q22-27, 5q12-14, 6p23-22, 12p13, 12q21-23, 13q31-34) were mapped to a set of 34 MLPA probes. The training set consisted of 39 BRCA1-likeaCGH breast cancers and 45 non-BRCA1-likeaCGH breast cancer patients, which had previously been analyzed by aCGH. Part of the sporadic tumors showing a BRCA1-likeaCGH profile had a low BRCA1 gene expression or BRCA1 promoter methylation. We trained a shrunken centroids classifier on the training set and validated in on an independent test set of 22 BRCA1-likeaCGH breast cancers and 19 non-BRCA1-likeaCGH breast cancer patients. Results: The training set of 84 patients could accurately be predicted by PAM (10-fold cross-validated accuracy, 94%). The classifier trained on the training set correctly predicted BRCA-like status of nearly all 41 breast tumors. Two out of 41 were misclassified, resulting in a specificity and sensitivity of both 95%. The assay performed equally well in identifying BRCA1 mutated as BRCA1-like patients. Conclusions: Since the MLPA assay can identify BRCA1-mutated and BRCA1-like sporadic breast cancer patients, this method could be both applied in clinical genetic testing, but also as a predictor of treatment benefit. BRCA1-like tumors are highly sensitive to chemotherapy with DNA damaging agents, and also to PARP-inhibitors. The MLPA assay is rapid and robust, can easily be multiplexed, and works well with DNA derived from paraffin-embedded tissues.
Toxicity evaluation of magnetic hyperthermia induced by remote actuation of magnetic nanoparticles in 3D micrometastasic tumor tissue analogs for triple negative breast cancer
Authors: Nathanael A. Stocke, Pallavi Sethi, Amar Jyoti, Ryan Chan, Susanne M. Arnold, J. Zach. Hilt, Meenakshi Upreti
Journal: Biomaterials (2016)
Abstract 2762: LFSpro: A risk assessment tool to estimate TP53 mutation status in families with Li-Fraumeni syndrome
Authors: Gang Peng, Jasmina Bojadzieva, Mandy L. Ballinger, David M. Thomas, Louise Strong, Wenyi Wang
Journal: Cancer Research (2015)

Abstract Li-Fraumeni syndrome (LFS) is a rare disorder and characterized by autosomal dominant mutation inheritance with frequent occurrence of multiple cancer types including soft tissue/bone sarcoma, breast cancer, leukemia, brain tumors and many others. A majority of LFS is caused by germ-line mutations in p53 tumor suppressor gene. Given the diverse cancer spectrum and incidence in Li-Fraumeni syndrome (LFS) and limitations of the clinical criteria, accurate identification of candidates for prospective TP53 mutation testing has been difficult. A more efficient prediction tool is needed for TP53 mutation carrier identification, which, followed by appropriate management and screening, may ultimately decrease mortality. To this date, we developed LFSpro, which is built on a Mendelian model and estimates TP53 mutation probability through the Elston-Stewart algorithm. With independent validation data from 765 families (19,530 individuals), we demonstrated the accurate prediction of TP53 mutation status using LFSpro. Family history of cancer evolves, and LFSpro is sensitive to mutation carriers in families newly presenting in high-risk clinics and in families followed for years. It is more broadly applicable than the current clinical criteria and therefore may improve clinical management for families with LFS. Citation Format: Gang Peng, Jasmina Bojadzieva, Mandy L. Ballinger, David M. Thomas, Louise Strong, Wenyi Wang. LFSpro: A risk assessment tool to estimate TP53 mutation status in families with Li-Fraumeni syndrome. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2762. doi:10.1158/1538-7445.AM2015-2762
Comparison of Donor Cell Homing Efficiency between Intraosseus and Intravenous Injection in Primate Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Feng Qi, Cindy M.L. Phua, Peik K. Tan, Pierce K.H. Chow, William Y.K. Hwang
Journal: Blood (2006)
Abstract 2614: Targeting heat shock protein 90 with Ganetespib for the treatment of lymphoma
Authors: Zhigang Tu, Hanqing Liu, Jingjing Zhao, Peishan Zhang, Zhiquan Liang, Lingling Ruan, Yongjin Lu, Dongsheng Shang, Ying Sun, Lili Xu, Keping Chen, Quji Danzeng
Journal: Cancer Research (2015)

Abstract Effective treatments for lymphoma remain a serious unmet medical need: the incidence of lymphoma continues to rise, and lymphoma tumors can relapse in patients who initially respond to treatment. Heat shock protein 90 (HSP90) has become an attractive therapeutic target in treating many many cancers, including blood cancers. In our study, we show that ganetespib, a clinically promising and actively investigated second-generation HSP90 inhibitor, dramatically reduced growth of a couple of different kinds of lymphoma, such as mantle cell lymphoma and Burkitt's lymphoma in a dose-dependent manner. It induced G2/M cell-cycle arrest and apoptosis in all studied cell lines, such as Ramos, Jeko-1, Granta-519, Raji, etc. Ganetespib significantly inhibited growth of xenograft tumors in vivo as a single agent or in combination with doxorubicin. Results of H&amp;E staining, TUNEL assays, and immunohistochemistry staining of Ki-67 revealed significant differences in ganetespib-treated tumors. Mechanistically, ganetespib caused pronounced decrease of expression of classic HSP90 client proteins. In summary, our data suggest that ganetespib can be potentially used for the molecularly targeted therapy of lymphoma patients. Citation Format: Zhigang Tu, Hanqing Liu, Jingjing Zhao, Peishan Zhang, Zhiquan Liang, Lingling Ruan, Yongjin Lu, Dongsheng Shang, Ying Sun, Lili Xu, Keping Chen, Quji Danzeng. Targeting heat shock protein 90 with Ganetespib for the treatment of lymphoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2614. doi:10.1158/1538-7445.AM2015-2614
Clinicopathological Features and Prognosis of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma with t(14;18) and 8q24 Translocation in the Rituximab Era
Authors: Nozomi Niitsu, Naoki Takahashi, Mika Kohri, Norio Asou, Jun-ichi Tamaru, Jun Sakai, Shigeo Nakamura, Ikuo Miura, Masataka Okamoto
Journal: Blood (2014)
OC-055 A prospective study validating a novel and simple polyp classification and comparing the outcomes between a Japanese expert and Western expert in a UK setting: Abstract OC-055
Authors: G R Longcroft-Wheaton, R Mead, T Uraoka, P Bhandari
Journal: Gut (2010)

<h3>Introduction</h3> Small hyperplastic Polyps have a very low malignant potential. However, they are currently being removed due to the lack of in-vivo histology techniques. Japanese endoscopists have published excellent results based on Kudo9s pit pattern. However, most of the published literature has used zoom endoscopy and vital stains, such as cresyl violet, and Kudo9s classification is difficult and inpractical to apply in a UK setting. Prospective validation of a new and easy mucosal pattern classification (NAC) Prospective comparison of the diagnostic accuracy of NAC classification when assessing colonic polyp using non-zoom endoscopes and indigo carmine dye spray. <h3>Methods</h3> NAC classification is based on three features: Mucosal patterns, vascular patterns and vascularity. Based on this polyps can be graded as N (non-neoplastic) A (adenoma) C (cancer). Fujinon non-zoom EC-590 colonoscopes with the EPX 4400 processor was used. Polyps were prospectively and independently assessed by a Japanese and a UK expert during screening colonoscopy, before and after indigo carmine dye spray. The lesions were subsequently removed to obtain the true diagnosis. MathCAD was used to process the statistics and chi2 test performed. <h3>Results</h3> A total of 121 polyps were evaluated. 60 polyp pictures from a prospective library for the validation exercise, and 61 polyps were prospectively examined during colonoscopy. Polyps evaluated during live endoscopy (61) showed the median polyp size was 7 mm (range 3–40 mm) (see Abstract 055). A chi2 test did not show any significant difference between the Japanese (Limb J) and UK (limb U) results (p=0.8). Sensitivity was 91% (J) and 87% (U). Specificity was 93% for J and U. Diagnostic accuracy was 92% (J) and 89% (U).
Severe Oral Ulcers Associated With Nivolumab Treatment
Authors: Takeshi Namiki, Takaaki Hanafusa, Makiko Ueno, Keiko Miura, Hiroo Yokozeki
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract 3915: Inhibition of cdc2 is linked to PMA-induced cell differentiation
Authors: Daria Vasilyeva, Pairat Dolinsky, Shashana Fielder, Alice Nakasone, Gerhild Packert, Xiaotang Hu
Journal: Cancer Research (2015)

Abstract The critical role of cdc2 (CDK1) in G2-M transition of the cell cycle control in mammalian cells has been well documented. Recent studies have also demonstrated that cdc2 is capable of driving G1 progress and G1-S transition via association with multiple interphase cyclins and through the interactions with Rb proteins. However, whether this pluripotent CDK regulates cell differentiation is unclear. Thus, the effect of phorbol 12-myristate 13-acetate (PMA) on cell differentiation and the expression of cdc2 in a human myeloid leukemia cell line, TF-1a, was investigated. When TF-1a cells were treated with 10−5, 10−6, and 10−7 PMA for 48 and 72h, they showed marked (≥50%) macrophage-like changes, evidenced by significant decrease in nucleus/cytoplasm ratio and increase (1-3 folds) in the expression of IL-1β, a macrophage marker. PMA treatment also caused time-dependent inhibition of cdc2 in both cytosol and nucleus of the cells, with a maximal inhibition being observed by 48 and 72h, which paralleled with the cell differentiation course. In contrast, there was no significant cell differentiation and inhibition of cdc2 being observed in control human myeloid leukemia TF-1 cells treated with PMA. Previous studies suggest that prolonged activation of MAPK pathway is linked to cell differentiation. PMA treatment also rapidly induced phosphorylation of MAPK kinases (MEK and ERK), which persisted for 24h, after which phosphorylated MEK and ERK were returned to base level, while the expression of cdc2 was still significantly downregulated, as compared with the control cells treated with DMSO. Pretreatment of TF-1a cells with sense cdc2 oligo nucleotides partially inhibited PMA-induced differentiation and upregulation of IL-1β. Taken together, our data suggest that MAPK pathway may be responsible for initiation of cell differentiation whereas inhibition of cdc2 is required for late differentiation of TF-1a cells in response to PMA stimulation. Whether activation of the MAPK pathway inhibits expression of cdc2 is currently under investigation (Supported by Faculty Incentive Grant and NIH-NIGMS MBRS RISE: R25 GM059244-13, Barry University). Note: This abstract was not presented at the meeting. Citation Format: Daria Vasilyeva, Pairat Dolinsky, Shashana Fielder, Alice Nakasone, Gerhild Packert, Xiaotang Hu. Inhibition of cdc2 is linked to PMA-induced cell differentiation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3915. doi:10.1158/1538-7445.AM2015-3915
Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Authors: Yanis Boumber, Deborah A. Thomas, Farhad Ravandi, Michael E. Rytting, Marian R Love, Hongbo Lu, Rebecca Garris, Jorge E. Cortes, Susan O'Brien, Jan A. Burger, Hagop M. Kantarjian, Marina Konopleva
Journal: Blood (2012)
Toxicity of the Oncoprotein LMP1 of Epstein Barr Virus as a New Mechanism of LMP1 Regulation Explaining the Heterogeneity of LMP1 Protein Levels in EBV-Transformed B-Cells.
Authors: Le Clorennec Christophe, Ouk Tan-Sothea, Jayat-Vignoles Chantal, Youlyouz-Marfak Ibtissam, Adriaenssens Eric, Coll Jean, Bordessoule Dominique, Feuillard Jean
Journal: Blood (2006)
OC-062 Longitudinal analysis of erosive and non-erosive gastro-oesophageal reflux disease: Abstract OC-062
Authors: N Powell, E A Russo, J Hoare, J Teare, R Negus, H Thomas, T R Orchard
Journal: Gut (2010)

<h3>Introduction</h3> Gastro-oesophageal reflux disease (GORD) is a common condition with a prevalence of about 20% in Western countries.1 In some patients GORD symptoms are associated with oesophageal mucosal injury, yet in others there is no macroscopic evidence of erosive disease. We sought to assess the natural history of patients with GORD symptoms with respect to the persistence or emergence of erosive disease over time, as well as the development of complications, including oesophageal strictures, Barrett9s epithelium (BE) and oesophageal cancer. <h3>Methods</h3> We analysed a database of over 50 000 oesophagogastroduodenoscopies (OGDs) performed at our unit between 1985 and 2006. From this database, we identified all patients undergoing OGD for GORD symptoms, who had subsequently undergone at least one further OGD at least 6 months after the index OGD. At the index OGD patients were categorised as having erosive oesophagitis (EE) or non-erosive reflux disease (NERD) based upon the presence or absence of mucosal injury. Changes or persistence of the index phenotype (EE or NERD) during follow-up OGDs were defined, as were the development of strictures, BE or oesophageal cancer. <h3>Results</h3> We identified 394 patients undergoing at least two OGDs for GORD symptoms. EE was present at the index endoscopy in 38% of patients (50% male, mean age 54 years) and NERD in 62% (53% male, mean age 54 years). Mean follow-up time was 4.8 years for EE and 5.2 years in NERD patients. Results of follow-up OGDs are shown in Abstract 062. <h3>Conclusion</h3> Patients with symptomatic GORD who undergo repeat OGD, even over extended time periods (mean follow-up 5 years) have a stable phenotype with respect to the persistence of EE or NERD, although NERD is significantly more likely to persist as a phenotype than EE. Patients with EE are significantly more prone to GORD complications.
Shellfish allergens: tropomyosin and beyond
Authors: M. A. Faber, M. Pascal, O. El Kharbouchi, V. Sabato, M. M. Hagendorens, I. I. Decuyper, C. H. Bridts, D. G. Ebo
Journal: Allergy (2016)

Abstract IgE‐mediated shellfish allergy constitutes an important cause of food‐related adverse reactions. Shellfish are classified into mollusks and crustaceans, the latter belonging to the class of arthropoda. Among crustaceans, shrimps are the most predominant cause of allergic reactions and thus more extensively studied. Several major and minor allergens have been identified and cloned. Among them, invertebrate tropomyosin, arginine kinase, myosin light chain, sarcoplasmic calcium‐binding protein, and hemocyanin are the most relevant. This review summarizes our current knowledge about these allergens.
205. Functional Assessment of NSE-Cre Mouse Model of Friedreich Ataxia
Authors: Mohammed Filali, Catherine Gérard, Jacques P. Tremblay
Journal: Molecular Therapy (2015)

The characterization of mouse models of human disease is essential for understanding the underlying pathophysiology and developing new therapeutics. To understand more clearly the pathogenesis of sensorimotor dysfunction in Friedreich ataxia, we used conditional knockout mice in which the frataxin gene had been knocked-out in some tissues during embryogenesis by breeding them with mice expressing the Cre recombinase gene under the NSE promoter. The NSE-Cre mice grew poorly compared to their controls, and demonstrated a severe neurologic phenotype, and a shorter life span. They exhibited extended duration of the hindlimb clasping response, as well as slowed movement time on a suspended bar, severe ataxic gait and kyphosis. The mutants have poor somatosensory perception, breathing difficulties, heart palpitation and autonomic dysfunction as indicated by urogenital failure. Despite the short life span, the NSE-Cre mice are a valid model to evaluate behavioral deficits and could be used to test experimental therapies to improve functional responses.
NIMG-46THE USE OF CLINICAL FUNCTIONAL MAGNETIC RESONANCE IMAGING IN BRAIN TUMOUR PATIENTS FOR SURGICAL PLANNING: A SINGLE-SURGEON RETROSPECTIVE COHORT STUDY AT A CANADIAN CENTER
Authors: Jonathan Lau, Joseph Megyesi
Journal: Neuro-Oncology (2015)

BACKGROUND: Advanced imaging techniques such as functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) are being increasingly used for the pre-operative evaluation of patients with brain tumors. METHODS: The study is a retrospective chart review investigating the use of fMRI from 2002-2013 in the pre-operative evaluation of brain tumour patients. Baseline demographic and clinical data were collected. The specific fMRI protocols used for each patient were recorded. RESULTS: 60 patients were identified over the twelve-year period. The type of tumours most commonly investigated were low-grade glioma, glioblastoma multiforme and meningioma. Most common presenting concerns were seizures (46%), change on surveillance (15%), language deficits (11%), and headache (10%). There was a predominance of left-hemispheric lesions investigated with fMRI (77.6% versus 22.4% for right). The most commonly involved lobes were frontal (46.5%), temporal (28.8%), parietal (16.4%), then insular (5.5%). The most common fMRI paradigms were language (85.2%), motor (79.6%), sensory (18.5%), and memory (9.3%). Most patients ultimately underwent a craniotomy (73.2%) while smaller groups underwent stereotactic biopsy (10.7%) and non-surgical management (16.1%). Time from request for fMRI to actual fMRI acquisition was 3.2 +/− 2.3 weeks. Time from fMRI acquisition to intervention was 5.2 +/− 5.4 weeks. CONCLUSIONS: We have characterized patient demographics in a retrospective single-surgeon cohort undergoing pre-operative clinical fMRI at a Canadian center. Our experience suggests an acceptable wait time from scan request to scan completion/analysis and from scan to intervention.
Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.
Authors: Luis Fayad, Hemant Patel, Gregor Verhoef, Myron Czuczman, James Foran, Eva Gine, Ama Rohatiner, Mitchell R. Smith, Mark Shapiro, Anjali Advani
Journal: Blood (2006)
A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys
Authors: Minh Diem Vu, Samuel Moser, Camille Delon, Melanie Latzko, Reto Gianotti, Remo Lüoend, Chloé Friang, Ramona Murr, Lydia Jasmin Duerner, Tina Weinzierl, Tanja Fauti, Marina Bacac, Oliver Ast, Anne Freimoser-Grundschober, Tea Rodriguez Diaz, Jörg Zielonka, Erwin van Puijenbroek, Ralf Hosse, Peter Bruenker, Ekkehard Mössner, Christian Klein, Pablo Umaña, Klaus Strein
Journal: Blood (2015)
Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.
Authors: Francesco Cavazzini, Jose A. Hernandez, Alessandro Gozzetti, Antonella Russo Rossi, Ruana Tiseo, Rossana Maffei, Antonella Bardi, Elisa Tammiso, Rosaria Crupi, Maria P. Lenoci, Roberto Marasca, Francesco Lauria, Giuseppe Torelli, Jesus M. Hernandez, Gian M. Rigolin, Antonio Cuneo
Journal: Blood (2007)